Facing the tidal wave
De-risking pharma and creating value for patients
The pharmaceutical industry is facing a ‘tidal wave’ of complex age and behaviour-related diseases creating increased economic, scientific and delivery risks. How can pharma companies evolve to overcome these obstacles?
Healthcare Information and Management Systems Society (HIMSS) Annual Conference 2017
Identification of Medicinal Products
Identification of Medicinal Products (IDMP) is one the biggest regulatory challenges for all pharmaceutical companies operating in Europe. How can your organisation navigate this journey towards increased patient safety and use it as an opportunity for business transformation?
Healthcare and Life Sciences Predictions 2020
Taxing times ahead
Tax is a hot topic right now for big business and will have major repercussions for the healthcare and life sciences industry. This paper explores the key tax challenges facing the industry and provides thought-provoking ideas to enable you to discuss future scenarios and how best to respond.
The challenge of compliance
Moving from cost to value
The life sciences industry faces unprecedented challenges amid increasing regulatory scrutiny. This latest Deloitte report explores the enterprise-wide compliance functions of major life science companies – identifying the big trends and opportunities to enable a move from cost to value.
China's healthcare provider market